MedTrace Logo

Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer

NCT00006682 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-08-14

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of vinorelbine combined with docetaxel in treating women who have metastatic breast cancer.

Conditions

Interventions

DRUG

docetaxel

Docetaxel 70mg/m2 on day 1 of every 21-day cycle

DRUG

vinorelbine ditartrate

Navelbine 20mg/m2 on Day 1 and D8 of a 21-day cycle

Sponsors & Collaborators

  • Medstar Health Research Institute

    lead OTHER

Principal Investigators

  • David J. Perry, MD · Medstar Health Research Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-02-29
Primary Completion
2002-01-22
Completion
2002-01-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00006682 on ClinicalTrials.gov